Optimization of the β-aminoester class of factor Xa inhibitors.: Part 2:: Identification of FXV673 as a potent and selective inhibitor with excellent in vivo anticoagulant activity

被引：50

作者：

Guertin, KR ^{[1
]}

Gardner, CJ ^{[1
]}

Klein, SI ^{[1
]}

Zulli, AL ^{[1
]}

Czekaj, M ^{[1
]}

Gong, Y ^{[1
]}

Spada, AP ^{[1
]}

Cheney, DL ^{[1
]}

Maignan, S ^{[1
]}

Guilloteau, JP ^{[1
]}

Brown, KD ^{[1
]}

Colussi, DJ ^{[1
]}

Chu, V ^{[1
]}

Heran, CL ^{[1
]}

Morgan, SR ^{[1
]}

Bentley, RG ^{[1
]}

Dunwiddie, CT ^{[1
]}

Leadley, RJ ^{[1
]}

Pauls, HW ^{[1
]}

机构：

[1] Aventis Pharmaceut, Drug Innovat & Approval, Bridgewater, NJ 08807 USA

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2002年 / 12卷 / 12期

关键词：

D O I：

10.1016/S0960-894X(02)00213-5

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Further optimization of the beta-aminoester class of factor Xa (fXa) inhibitors is described culminating in the identification of 9c (FXV673), a potent and selective factor Xa inhibitor with excellent in vivo anticoagulant activity. An X-ray structure of FXV673 bound to human fXa is also presented. Based on its selectivity, potent in vivo activity and favorable pre-clinical safety profile, FXV673 was selected for further development and is currently undergoing clinical trials. (C) 2002 Elsevier Science Ltd. All rights reserved.

引用

页码：1671 / 1674

页数：4

共 20 条

[11] Novastan® (brand of argatroban):: A small-molecule, direct thrombin inhibitor [J].

Hursting, MJ ;

Alford, KL ;

Becker, JCP ;

Brooks, RL ;

Joffrion, JL ;

Knappenberger, GD ;

Kogan, PW ;

Kogan, TP ;

McKinney, AA ;

Schwarz, RP .

SEMINARS IN THROMBOSIS AND HEMOSTASIS, 1997, 23 (06) :503-516

[12]

JORDAN RE, 1999, BIOPHARM IND PERSPEC, V35

[13] FACTOR XA INHIBITORS AS NOVEL ANTITHROMBOTIC AGENTS - FACTS AND PERSPECTIVES [J].

KAISER, B ;

HAUPTMANN, J .

CARDIOVASCULAR DRUG REVIEWS, 1994, 12 (03) :225-236

[14] Pharmacokinetics and pharmacodynamics of glycoprotein IIb-IIIa inhibitors [J].

Kleiman, NS .

AMERICAN HEART JOURNAL, 1999, 138 (04) :S263-S275

[15] Identification and initial structure-activity relationships of a novel class of nonpeptide inhibitors of blood coagulation factor Xa [J].

Klein, SI ;

Czekaj, M ;

Gardner, CJ ;

Guertin, KR ;

Cheney, DL ;

Spada, AP ;

Bolton, SA ;

Brown, K ;

Colussi, D ;

Heran, CL ;

Morgan, SR ;

Leadley, RJ ;

Dunwiddie, CT ;

Perrone, MH ;

Chu, V .

JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (04) :437-450

[16]

Leadley Robert J. Jr., 2001, Current Topics in Medicinal Chemistry, V1, P151

[17] New data on the pharmacology of heparin and low molecular weight heparins [J].

Samama, MM ;

Bara, L ;

GouinThibault, L .

DRUGS, 1996, 52 :8-14

[18]

SCHMAIER AH, 2000, HANDB EXP PHARM, V140, P277

[19] Heparin-induced thrombocytopenia, paradoxical thromboembolism, and other side effects of heparin therapy [J].

Walenga, JM ;

Bick, RL .

MEDICAL CLINICS OF NORTH AMERICA, 1998, 82 (03) :635-+

[20]

WEITZ JL, 1994, BIOCHIM BIOPHYS ACTA, V1227, P113

← 1 2 →